MedinCell Signs a Licence Agreement With the Medicines Patent Pool to Fight Malaria Transmission, as Part of Its Global Health Mission

The licence agreement complements the collaboration between Medincell and the health agency Unitaid that funds the development of mdc-STM, an investigational long-acting injectable formulation for the prevention of malaria.

The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to, and facilitate the development of life-saving medicines for low- and middle-income countries.

The licence agreement relates to a 3-Month active injectable formulation of ivermectin using Medincell’s BEPO^® technology to fight malaria transmission.

The licence agreement aims to ensure that the product be widely distributed in low- and middle-income countries if proven effective and safe.

Malaria remains endemic in 91 countries leading to 627,000 deaths in 2020. Children under 5 are the most vulnerable, accounting for 80% of deaths.

GENEVA, Switzeland & JACOU, France--(BUSINESS WIRE)--Regulatory News:

The Medicines Patent Pool (MPP) and French pharmaceutical company MedinCell (Paris:MEDCL) today announced that they have signed a licence agreement for a candidate long-acting drug formulation that could be used to fight malaria in low- and middle-income countries.

This non-exclusive licence agreement, made possible with funding to both parties from global health agency Unitaid, will enable MPP to support the identification of suitable partners for the development and commercialisation of mdc-STM, an injectable formulation of ivermectin with a three-month action-duration, using MedinCell’s BEPO^® technology. Under the terms of the licence, the manufacturing can be carried out in any country worldwide, for distribution in low- and middle-income countries.

Now at a pre-clinical stage, the product is based on BEPO®, a MedinCell polymer-based injectable technology that enables the sustained release of ivermectin after a single injection administered subcutaneously at the beginning of the malaria transmission season to people living in malaria-endemic areas. Mosquitoes feeding on persons having received ivermectin injections will be killed or made less capable of transmitting malaria parasites further. Through this community-based intervention – the individual receiving the injection will not be protected against malaria directly - the number of mosquitoes will be decreased, thus benefiting the whole community by lowering the risk of transmission of malaria, particularly in children.

If proven safe, effective and acceptable, this long-acting injectable candidate could have a significant impact on transmission of malaria among vulnerable populations in high-transmission areas, in particular young children who are adversely affected.

“We are very proud to be partnering with MedinCell to accelerate the development of such paradigm-changing interventions and ensure these innovations, if proven safe and effective, are available in low- and middle-income countries as soon as possible” said Charles Gore, Executive Director of MPP.

“This long-acting technology offers an exciting new avenue in the fight against malaria, and this licence is key to allow rapid access to innovation for those who need it most.”

Malaria remains endemic in 91 countries representing 50% of the world’s population. According to WHO estimates, 241 million people were infected worldwide in 2020, 95% of them in Africa, leading to 627,000 deaths. Children under 5 are the most vulnerable, accounting for 80% of deaths from malaria.

“Collaboration and innovation are key to face major Global Health challenges, said Christophe Douat, CEO of MedinCell. Bringing together the best players to move this project forward is crucial to ensure that this innovative product based on our long-acting Injectable technology, if proven safe and effective, can have a positive impact for affected population. We are delighted to join forces with MPP which could play an essential role in enabling rapid and global access to this new complementary tool to fight the malaria scourge.”

This successful early-stage collaboration is part of Unitaid’s larger strategy to accelerate the development of affordable, quality, long-acting products for infectious diseases. As part of that work, Unitaid is funding both MedinCell to develop long-acting antimalarial products and MPP to facilitate generic production of the new technologies without delay. “In the fight against malaria, there is no time to lose. We know that, if proven safe and effective, this long-acting malaria prevention will hold tremendous potential. By supporting development and access pathways simultaneously, Unitaid is investing on all fronts to fast-track access to new malaria fighting tools,” said Dr Philippe Duneton, Executive Director of Unitaid.

The licence agreement covers all low- and middle-income countries and is royalty free in the public sector, with reasonable royalty in line with industry standards to be agreed in case there would be a private market for the licensed product in low and middle- income countries.

Access the licence agreement

The press release is also available in French and Spanish (translation by MPP).

More on MPP’s work in long-acting therapeutics

About MPP

The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to, and facilitate the development of, life-saving medicines for low- and middle-income countries. Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups, and other stakeholders, to prioritise and license needed medicines and pool intellectual property to encourage generic manufacture and the development of new formulations.

To date, MPP has signed agreements with 16 patent holders for 13 HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals, a tuberculosis treatment, four long-acting technologies, two oral antiviral treatments for COVID-19 and 12 COVID-19 technologies. MPP was founded by Unitaid, which continues to be MPP’s main funder. MPP’s work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC). MPP’s activities in COVID-19 are undertaken with the financial support of the Japanese Government, the French Ministry for Europe and Foreign Affairs, and SDC.

About MedinCell

MedinCell is a pharmaceutical company at premarketing stage that develops a portfolio of long-acting injectable products in various therapeutic areas by combining its proprietary BEPO^® technology with active ingredients already known and marketed. Through the controlled and extended release of the active pharmaceutical ingredient, MedinCell makes medical treatments more efficient, particularly thanks to improved compliance, i.e. compliance with medical prescriptions, and to a significant reduction in the quantity of medication required as part of a one-off or chronic treatment. The BEPO^® technology makes it possible to control and guarantee the regular delivery of a drug at the optimal therapeutic dose for several days, weeks or months starting from the subcutaneous or local injection of a simple deposit of a few millimeters, fully bioresorbable. MedinCell collaborate with tier one pharmaceuticals companies and foundations to improve Global Health through new therapeutic options. Based in Montpellier, MedinCell currently employs more than 150 people representing over 30 different nationalities.
www.medincell.com

This press release contains forward-looking statements, including statements regarding Company’s expectations for (i) the timing, progress and outcome of its clinical trials; (ii) the clinical benefits and competitive positioning of its product candidates; (iii) its ability to obtain regulatory approvals, commence commercial production and achieve market penetration and sales; (iv) its future product portfolio; (v) its future partnering arrangements; (vi) its future capital needs, capital expenditure plans and ability to obtain funding; and (vii) prospective financial matters regarding our business. Although the Company believes that its expectations are based on reasonable assumptions, any statements other than statements of historical facts that may be contained in this press release relating to future events are forward-looking statements and subject to change without notice, factors beyond the Company's control and the Company's financial capabilities.

These statements may include, but are not limited to, any statement beginning with, followed by or including words or phrases such as "objective", "believe", "anticipate", “expect”, "foresee", "aim", "intend", "may", "anticipate", "estimate", "plan", "project", "will", "may", "probably", “potential”, "should", "could" and other words and phrases of the same meaning or used in negative form. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that may, if any, cause actual results, performance, or achievements to differ materially from those anticipated or expressed explicitly or implicitly by such forward-looking statements. A list and description of these risks, contingencies and uncertainties can be found in the documents filed by the Company with the Autorité des Marchés Financiers (the "AMF") pursuant to its regulatory obligations, including the Company's registration document, registered with the AMF on September 4, 2018, under number I. 18-062 (the "Registration Document"), as well as in the documents and reports to be published subsequently by the Company. In particular, readers' attention is drawn to the section entitled "Facteurs de Risques" on page 26 of the Registration Document.

Any forward-looking statements made by or on behalf of the Company speak only as of the date they are made. Except as required by law, the Company does not undertake any obligation to publicly update these forward-looking statements or to update the reasons why actual results could differ materially from those anticipated by the forward-looking statements, including in the event that new information becomes available. The Company's update of one or more forward-looking statements does not imply that the Company will make any further updates to such forward-looking statements or other forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements.

This press release is for information purposes only. The information contained herein does not constitute an offer to sell or a solicitation of an offer to buy or subscribe for the Company's shares in any jurisdiction, in particular in France. Similarly, this press release does not constitute investment advice and should not be treated as such. It is not related to the investment objectives, financial situation, or specific needs of any recipient. It should not deprive the recipients of the opportunity to exercise their own judgment. All opinions expressed in this document are subject to change without notice. The distribution of this press release may be subject to legal restrictions in certain jurisdictions. Persons who come to know about this press release are encouraged to inquire about, and required to comply with, these restrictions.

MPP
press@medicinespatentpool.org

MedinCell
David Heuzé
Communication leader
david.heuze@medincell.com
+33 (0)6 83 25 21 86

NewCap
Louis-Victor Delouvrier/Mathilde Bohin
Investor Relations
medincell@newcap.eu
+33 (0)1 44 71 94 94

NewCap
Nicolas Merigeau
Media Relations
medincell@newcap.eu
+33 (0)1 44 71 94 94